Colorescience completed a $30 million debt financing with K2 HealthVentures, a healthcare-focused specialty finance company. Colorescience received the first tranche of $20 million and fully repaid its previous $17.5 million loan facility with Midcap Financial Services.
K2 HealthVentures will provide a debt financing facility for up to $50 million to VBI Vaccines, a commercial-stage biopharmaceutical company developing infectious disease and immuno-oncology vaccines.
K2 HealthVentures provided an up to $45 million debt financing facility to Molecular Templates. Molecular Templates received a first tranche of $15 million upon closing.
K2 HealthVentures provided a $45 million loan and security agreement to Inari, a biotechnology company developing next-generation seeds.